Experimental lymphoma drug trial halted early
NCT ID NCT05179603
Summary
This study tested an experimental drug called SAR444245, both alone and combined with other cancer treatments, for people with advanced B-cell lymphoma that had returned or stopped responding to previous therapies. It involved 14 participants aged 12 and older who had already tried at least two other treatments. The main goals were to see if the drug was safe and if it could shrink tumors, but the study was terminated early.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes NO responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for DIFFUSE LARGE B-CELL LYMPHOMA are added.
By submitting, you agree to our Terms of use
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Locations
-
Investigational Site Number : 0320005
CABA, Buenos Aires, 1430, Argentina
-
Investigational Site Number : 1520001
Temuco, 4800827, Chile
-
Investigational Site Number : 1520002
Santiago, Reg Metropolitana de Santiago, 7500921, Chile
-
Investigational Site Number : 1520003
Santiago, Reg Metropolitana de Santiago, 7500653, Chile
-
Investigational Site Number : 1520004
Viña del Mar, Región de Valparaíso, 2540488, Chile
-
Investigational Site Number : 7240001
L'Hospitalet de Llobregat, Barcelona [Barcelona], 08908, Spain
-
Investigational Site Number : 7240002
Barcelona, Barcelona [Barcelona], 08036, Spain
-
Investigational Site Number : 7240004
Madrid / Madrid, Madrid, Comunidad de, 28040, Spain
Conditions
Explore the condition pages connected to this study.